Efficacy and safety of prolonged-release melatonin for insomnia in middle-aged and elderly patients with hypertension: A combined analysis of controlled clinical trials

Integrated Blood Pressure Control

Volumn 5, Issue , 2012, Pages 9-17

  Lemoine, Patrick ^a   Wade, Alan G ^b   Katz, Amnon ^a   Nir, Tali ^c   Zisapel, Nava ^c,d  

^a Clinique Lyon Lumiere   (France)

^b CPS Research   (United Kingdom)

^c NEURIM PHARMACEUTICALS LTD   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

Cardiovascular disease; Hypertension; Insomnia; Nocturnal blood pressure; Prolonged release melatonin; Sleep quality

Indexed keywords

MELATONIN; PLACEBO;

ADULT; AGED; ALERTNESS; ANTIHYPERTENSIVE THERAPY; ARTICLE; BEDTIME DOSAGE; BEHAVIORAL SCIENCE; BLOOD PRESSURE MEASUREMENT; CLINICAL ASSESSMENT TOOL; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; GERIATRIC PATIENT; HUMAN; HYPERTENSION; INFECTION; INSOMNIA; LEEDS SLEEP EVALUATION QUESTIONNAIRE SCORE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MIDDLE AGED; NEUROLOGIC DISEASE; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SLEEP QUALITY; SUSTAINED DRUG RELEASE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

EID: 84857077943     PISSN: None     EISSN: 11787104     Source Type: Book Series    
DOI: 10.2147/IBPC.S27240     Document Type: Article

References (47)

1. Bliwise DL, King AC, Harris RB, Haskell WL. Prevalence of selfreported poor sleep in a healthy population aged 50-65. Soc Sci Med. 1992;34(1):49-55.
2. Fullerton DS. The economic impact of insomnia in managed care: a clearer picture emerges. Am J Manag Care. 2006;12(Suppl 8):S246-S252.
3. Leger D, Poursain B, Neubauer D, Uchiyama M. An international survey of sleeping problems in the general population. Curr Med Res Opin. 2008;24(1):307-317.
4. Ohayon MM, Sagales T. Prevalence of insomnia and sleep characteristics in the general population of Spain. Sleep Med. 2010;11(10):1010-1018.
5. Roth T. Insomnia: definition, prevalence, etiology, and consequences. J Clin Sleep Med. 2007;3(Suppl 5):S7-S10.
6. Roth T, Roehrs T. Insomnia: epidemiology, characteristics, and consequences. Clinical Cornerstone Chronic Insomnia. 2003; 5(3):5-15.
7. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension,1988-2008. JAMA. 2010; 303(20):2043-2050.
8. Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA. 2003;289(18):2363-2369.
9. Roth T. Comorbid insomnia: current directions and future challenges. Am J Manag Care. 2009;Suppl 15:S6-S13.
10. Lanfranchi PA, Pennestri MH, Fradette L, Dumont M, Morin CM, Montplaisir J. Nighttime blood pressure in normotensive subjects with chronic insomnia: implications for cardiovascular risk. Sleep. 2009;32(6):760-766.
11. Gangwisch JE, Malaspina D, Posner K, et al. Insomnia and sleep duration as mediators of the relationship between depression and hypertension incidence. Am J Hypertens. 2010;23(1):62-69.
12. Gangwisch JE, Heymsfield SB, Boden-Albala B, et al. Short sleep duration as a risk factor for hypertension: analyses of the first National Health and Nutrition Examination Survey. Hypertension. May 2006; 47(5):833-839.
13. Fung MM, Peters K, Redline S, et al. Decreased slow wave sleep increases risk of developing hypertension in elderly men. Hypertension. 2011;58(4):596-603.
14. Hermida RC, Ayala DE, Mojon A, Fernandez JR. Decreasing sleep-time blood pressure determined by ambulatory monitoring reduces cardiovascular risk. J Am Coll Cardiol. 2011;58(11):1165-1173.
15. Hoevenaar-Blom MP, Spijkerman AMW, Kromhout D, van den Berg JF, Verschuren WMM. Sleep duration and sleep quality in relation to 12-year cardiovascular disease incidence: the MORGEN Study. Sleep. In press. 2011.
16. Grossman E, Laudon M, Zisapel N. Effect of melatonin on nocturnal blood pressure: meta-analysis of randomized controlled trials. Vasc Health Risk Manag. 2011;7:577-584.
17. Wade A, Zisapel N, Lemoine P. Prolonged-release melatonin for the treatment of insomnia: targeting quality of sleep and morning alertness. Aging Health. 2008;1:11-21.
18. Czeisler CA, Duffy JF, Shanahan TL, et al. Stability, precision, and near-24-hour period of the human circadian pacemaker. Science. 1999;284(5423):2177-2181.
19. Hofman MA, Swaab DF. Alterations in circadian rhythmicity of the vasopressin-producing neurons of the human suprachiasmatic nucleus (SCN) with aging. Brain Res. 1994;651(1-2):134-142.
20. Mahlberg R, Kienast T, Hadel S, Heidenreich JO, Schmitz S, Kunz D. Degree of pineal calcification (DOC) is associated with polysomnographic sleep measures in primary insomnia patients. Sleep Med. 2009;10(4):439-445.
21. Waldhauser F, Weiszenbacher G, Tatzer E, et al. Alternations in nocturnal serum melatonin levels in humans with growth and aging. J Clin Endocrinol Metab. 1988;66:648-652.
22. Haimov I, Laudon M, Zisapel N, et al. Sleep disorders and melatonin rhythms in elderly people. BMJ. 1994;309:167.
23. Leger D, Laudon M, Zisapel N. Nocturnal 6-sulfatoxymelatonin excretion in insomnia and its relation to the response to melatonin replacement therapy. Am J Med. 2004;116(2):91-95.
24. Lemoine P, Garfinkel D, Laudon M, Nir T, Zisapel N. Prolonged release melatonin for insomnia - an open label long term study of efficacy, safety and withdrawal symptoms Ther Clin Risk Manag. 2011;7: 301-311.
25. Lemoine P, Nir T, Laudon M, Zisapel N. Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects. J Sleep Res. 2007;16:372-380.
26. Luthringer R, Muzet M, Zisapel N, Staner L. The effect of prolongedrelease melatonin on sleep measures and psychomotor performance in elderly patients with insomnia. Int Clin Psychopharmacol. 2009;24(5): 239-249.
27. Wade AG, Ford I, Crawford G, et al. Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety. BMC Med. 2010;8(1):51.
28. Wade AG, Ford I, Crawford G, et al. Efficacy of prolonged release melatonin in insomnia patients aged 55-80 years: quality of sleep and next-day alertness outcomes. Curr Med Res Opin. 2007;23(10): 2597-2605.
29. Zisapel N. Laudon M. Subjective assessment of the effects of CNSactive drugs on sleep by the Leeds Sleep Evaluation Questionnaire: a review. Human Psychopharmacology Clin Exp. 2002;17:1-19.
30. Parrott AC, Hindmarch I. The Leeds Sleep Evaluation Questionnaire in psychopharmacological investigations - a review. Psychopharmacology (Berl). 1980;71(2):173-179.
31. Tarrasch R, Laudon M, Zisapel N. Cross-cultural validation of the Leeds Sleep Evaluation Questionnaire (LSEQ) in insomnia patients. Hum Psychopharmacol. 2003;18(8):603-610.
32. Guy W. ECDEU assessment manual for psychopharmacology (rev, 1976): Kensington: DHEW publication. Biometric laboratory, George Washington University, US Department of Health, Education and Welfare; 1976.
33. Cohen J. Statistical power analysis for the behavioral sciences. Hillsdale, NJ: Lawrence Earlbaum Associates; 1988.
34. Glass J, Lanctot KL, Herrmann N, Sproule BA, Busto UE. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ. 2005;331(7526):1169.
35. Claghorn JL, Kiev A, Rickels K, Smith WT, Dunbar GC. Paroxetine versus placebo: a double-blind comparison in depressed patients. J Clin Psychiatry. 1992;53(12):434-438.
36. Schneider LS, Ismail MS, Dagerman K, et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer's disease trial. Schizophr Bull. 2003;29(1):57-72.
37. de la Sierra A, Redon J, Banegas JR, et al. Prevalence and factors associated with circadian blood pressure patterns in hypertensive patients. Hypertension. 2009;53:466-472.
38. McCann CC, Quera-Salva MA, Boudet J, et al. Effect of zolpidem during sleep on ventilation and cardiovascular variables in normal subjects. Fundam Clin Pharmacol. 1993;7(6):305-310.
39. Rachmani R, Shenhav G, Slavachevsky I, Levy Z, Ravid M. Use of a mild sedative helps to identify true non-dippers by ABPM: a study in patients with diabetes mellitus and hypertension. Blood Press Monit. 2004;9(2):65-69.
40. Rommel T, Demisch L. Influence of chronic b-adrenoreceptor blocker treatment on melatonin secretion and sleep quality in patients with essential hypertension. J Neural Transm. 1994;95:39-48.
41. Tanabe N, Fujita T, Fujii Y, Orii T. Investigation of the factors that contribute to the onset of insomnia in hypertensive patients by using a post-marketing surveillance database. Yakugaku Zasshi. 2011; 131(5):669-677.Japanese.
42. Brugger P, Marktl W, Herold M. Impaired nocturnal secretion of melatonin in coronary heart disease. Lancet. 1995;345(8962):1408.
43. Jonas M, Garfinkel D, Zisapel N, Laudon M, Grossman E. Impaired nocturnal melatonin secretion in non-dipper hypertensive patients. Blood Press. 2003;12:19-24.
44. Rapoport SI, Shatalova AM, Malinovskaia NK, Vettenberg L. Melatonin production in hypertensive patients. Klin Med (Mosk). 2000;78(6): 21-24.Russian.
45. Sakotnik A, Liebmann PM, Stoschitzky K, et al. Decreased melatonin synthesis in patients with coronary artery disease. Eur Heart J. 1999;20(18):1314-1317.
46. Stoschitzky K, Sakotnik A, Lercher P, et al. Influence of beta-blockers on melatonin release. Eur J Clin Pharmacol. 1999;55(2):111-115.
47. Stoschitzky K, Stoschitzky G, Brussee H, Bonelli C, Dobnig H. Comparing beta-blocking effects of bisoprolol, carvedilol and nebivolol. Cardiology. 2006;106(4):199-206.